Valuation: Sera Prognostics, Inc.

Market Cap 80.28M 70.51M 65.57M 60.17M 113M 7.73B 115M 779M 304M 3.8B 301M 295M 13.14B P/E 2026 *
-3.13x
P/E 2027 * -3.66x
Enterprise Value 80.28M 70.51M 65.57M 60.17M 113M 7.73B 115M 779M 304M 3.8B 301M 295M 13.14B EV / Sales 2026 *
221x
EV / Sales 2027 * 30x
Free-Float
85.93%
Yield 2026 *
-
Yield 2027 * -
1 day-5.53%
Current month+12.64%
1 month+13.89%
3 months+1.99%
6 months-36.73%
Current year-30.51%
1 week 1.92
Extreme 1.9201
2.3
1 month 1.74
Extreme 1.74
2.3
Current year 1.56
Extreme 1.56
3.85
1 year 1.56
Extreme 1.56
3.95
3 years 1.37
Extreme 1.37
12.36
5 years 1.1
Extreme 1.1
13.51
10 years 1.1
Extreme 1.1
15.5
Manager TitleAgeSince
Chief Executive Officer 52 2023-05-31
Director of Finance/CFO 39 2023-06-06
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Director/Board Member 68 2021-11-28
Director/Board Member 64 2026-06-30
Chairman 74 2011-04-19
Date Insider Type Main position Quantity % Market Cap.
7/10/26 Free

Director

62,657 0.1641%
7/10/26 Free

Director

62,697 0.1642%
7/10/26 Free

Chairman

65,604 0.1718%
Change 5-day change 1-year change 3-year change Capi.($)
-5.53%0.00%-36.92%-33.22% 80.28M
-2.67%-2.08%+11.62%+12.67% 22.59B
+0.60%-1.32%+22.59% - 17.23B
-1.54%+0.98%+5.85%-31.93% 3.31B
-0.63%+1.13%+20.91%+0.28% 2.49B
-1.99%+9.01%-32.04%-38.71% 2.04B
+2.30%+4.09%-40.28% - 1.58B
-2.09%-2.80%-8.49%+0.50% 1.45B
-4.35%-20.08%+66.26%+97.92% 1.43B
-2.15%+1.96%-16.69%-5.32% 1.28B
Average -1.80%+0.34%-0.72%+0.27% 5.35B
Weighted average by Cap. -1.30%-0.91%+12.20%+6.74%

Financials

2026 *2027 *
Net sales 362K 318K 296K 272K 511K 34.91M 518K 3.52M 1.37M 17.16M 1.36M 1.33M 59.34M 2.68M 2.35M 2.18M 2M 3.77M 258M 3.83M 25.95M 10.14M 127M 10.04M 9.83M 438M
Net income -33.26M -29.21M -27.17M -24.93M -46.84M -3.2B -47.56M -323M -126M -1.57B -125M -122M -5.44B -29.98M -26.33M -24.49M -22.47M -42.22M -2.89B -42.87M -291M -114M -1.42B -113M -110M -4.91B
Net Debt - -
Logo Sera Prognostics, Inc.
Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.
Employees
72
Date Price Change Volume
26-07-24 US$2.050 -5.53% 18,939
26-07-23 US$2.170 +4.33% 20,678
26-07-22 US$2.080 -8.37% 23,579
26-07-21 US$2.270 +8.10% 91,813
26-07-20 US$2.100 +2.44% 27,447
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.050USD
Average target price
5.500USD
Spread / Average Target
+168.29%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SERA Stock